Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Holkira Pak | Ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Holkira Pak | ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Botox | OnabotulinumtoxinA | Neurogenic detrusor overactivity | List with clinical criteria and/or conditions | Complete | ||
| Botox | OnabotulinumtoxinA | Migraine | Do not list | Complete | ||
| Botox | OnabotulinumtoxinA | Urinary incontinence | List with criteria/condition | Complete | ||
| Zolgensma | onasemnogene abeparvovec | Spinal muscular atrophy (SMA), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | |||
| Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tagrisso | osimertinib | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 19, 2024